Showing results (161-170 of 212) with videos related to

Sort By:
Pageof 22
Circulation|September 6, 2014
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trialBenjamin M Scirica, Eugene Braunwald, Itamar Raz, et al.
The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.
Circulation|May 28, 2009
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial, John H Alexander, Richard C Becker, et al.
European Heart Journal|October 23, 2013
Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trialJohn H Alexander, Renato D Lopes, Laine Thomas, et al.
Neurology|March 1, 2019
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyJackie Bosch, Martin O'Donnell, Balakumar Swaminathan, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|May 5, 2018
Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of CardiologyGiuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, et al.
The New England Journal of Medicine|April 1, 2009
Early versus delayed, provisional eptifibatide in acute coronary syndromesRobert P Giugliano, Jennifer A White, Christoph Bode, et al.
Diabetes Care|June 22, 2025
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER TrialYu Mi Kang, Robert P Giugliano, Xinhui Ran, et al.
JAMA Cardiology|April 30, 2020
An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER TrialBrian A Bergmark, Michelle L O'Donoghue, Sabina A Murphy, et al.
American Heart Journal|December 24, 2018
The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarctionC Michael Gibson, Mathieu Kerneis, Megan K Yee, et al.
Pageof 22